Rothschild Capital Partners Exits Position in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Rothschild Capital Partners has sold out all of its stake in Celgene Corporation during the most recent quarter, according to the disclosure filed by the company on Jul 26, 2016 with the SEC. The investment management company has sold out 2,000 shares of Celgene Corporation which is valued at $216,220.

Other Hedge Funds, Including , Aviance Capital Management boosted its stake in CELG in the latest quarter, The investment management firm added 430 additional shares and now holds a total of 2,431 shares of Celgene Corporation which is valued at $262,815. Celgene Corporation makes up approx 0.01% of Aviance Capital Management’s portfolio.Ls Investment Advisors boosted its stake in CELG in the latest quarter, The investment management firm added 152 additional shares and now holds a total of 10,690 shares of Celgene Corporation which is valued at $1,149,389. Celgene Corporation makes up approx 0.08% of Ls Investment Advisors’s portfolio.Fox Run Management L.l.c. reduced its stake in CELG by selling 6,500 shares or 60.19% in the most recent quarter. The Hedge Fund company now holds 4,300 shares of CELG which is valued at $449,866. Celgene Corporation makes up approx 0.21% of Fox Run Management L.l.c.’s portfolio.Boys Arnold Co Inc boosted its stake in CELG in the latest quarter, The investment management firm added 10,044 additional shares and now holds a total of 21,709 shares of Celgene Corporation which is valued at $2,229,514. Celgene Corporation makes up approx 0.37% of Boys Arnold Co Inc’s portfolio.Boltwood Capital Management boosted its stake in CELG in the latest quarter, The investment management firm added 395 additional shares and now holds a total of 5,795 shares of Celgene Corporation which is valued at $580,949. Celgene Corporation makes up approx 0.48% of Boltwood Capital Management’s portfolio.

Celgene Corporation opened for trading at $110.66 and hit $112.43 on the upside on Friday, eventually ending the session at $112.19, with a gain of 0.84% or 0.93 points. The heightened volatility saw the trading volume jump to 54,86,248 shares. Company has a market cap of $86,903 M.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *